Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSNASDAQ:ARDSNASDAQ:JAGXNASDAQ:YMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.49-2.2%$3.42$3.96▼$12.00$6.26M1.557,305 shs4,018 shsARDSAridis Pharmaceuticals$0.00$0.00$0.00▼$0.08$5K12.098,404 shs40,000 shsJAGXJaguar Animal Health$2.80+0.7%$6.16$2.73▼$110.75$2.83M0.6852,001 shs85,313 shsYMTXYumanity Therapeutics$0.68$0.95▼$3.78$7.46M0.32473,083 shs6,790 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris0.00%-0.89%-0.89%-17.97%-41.12%ARDSAridis Pharmaceuticals0.00%0.00%0.00%0.00%-99.86%JAGXJaguar Animal Health0.00%-27.42%-52.40%-51.86%-97.16%YMTXYumanity Therapeutics0.00%0.00%0.00%0.00%+37.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar Animal Health2.0642 of 5 stars3.55.00.00.00.00.00.6YMTXYumanity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AARDSAridis Pharmaceuticals 0.00N/AN/AN/AJAGXJaguar Animal Health 3.00Buy$60.002,042.86% UpsideYMTXYumanity Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest JAGX, YMTX, ARDS, and AEZS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.64N/AN/A$14.99 per share0.23ARDSAridis Pharmaceuticals$3.09M0.00N/AN/AN/A∞JAGXJaguar Animal Health$11.69M0.24N/AN/A$12.29 per share0.23YMTXYumanity Therapeutics$4.84M0.00N/AN/A$2.28 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)ARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/AJAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)YMTXYumanity Therapeutics-$39.50M-$3.00N/AN/AN/A-660.61%-263.34%-107.08%N/ALatest JAGX, YMTX, ARDS, and AEZS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AYMTXYumanity TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93ARDSAridis PharmaceuticalsN/AN/AN/AJAGXJaguar Animal Health22.201.080.70YMTXYumanity TherapeuticsN/A2.212.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%ARDSAridis Pharmaceuticals9.65%JAGXJaguar Animal Health12.04%YMTXYumanity Therapeutics25.10%Insider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%ARDSAridis Pharmaceuticals5.50%JAGXJaguar Animal Health0.38%YMTXYumanity Therapeutics12.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableJAGXJaguar Animal Health501.02 million1.01 millionNo DataYMTXYumanity Therapeutics4010.86 million9.50 millionNot OptionableJAGX, YMTX, ARDS, and AEZS HeadlinesRecent News About These CompaniesBoard of GovernorsJuly 20, 2024 | bc.eduJSPR Jasper Therapeutics, Inc.March 20, 2024 | seekingalpha.comCara Therapeutics Inc CARANovember 3, 2023 | morningstar.comYumanity Therapeutics Inc.October 6, 2023 | thestreet.comFormer Onyx CEO Returns to Biotech to Launch Boston Start UpJuly 5, 2023 | thestreet.comKineta raises $6M through registered direct offeringMay 1, 2023 | bizjournals.comColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus ReportsFebruary 22, 2023 | finance.yahoo.comYumanity Therapeutics's Return On Capital Employed InsightsDecember 26, 2022 | msn.comKineta finalizes reverse merger with Yumanity, secures additional fundingDecember 20, 2022 | bizjournals.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ...December 5, 2022 | bakersfield.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with KinetaDecember 5, 2022 | finance.yahoo.comWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?December 5, 2022 | investorplace.comYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finanznachrichten.deYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finance.yahoo.comYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.November 10, 2022 | finance.yahoo.comYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with KinetaAugust 29, 2022 | finance.yahoo.comYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsAugust 4, 2022 | finance.yahoo.comGlioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless OpportunitiesJuly 14, 2022 | medgadget.comYUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of…July 5, 2022 | lawyer-monthly.comInside Kineta's plans after unveiling reverse merger dealJune 8, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValuePfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumBy Jeffrey Neal Johnson | May 22, 2025View Archer Rebuts Short Seller, Points to Strong Q1 & Global MomentumWhy Amazon Could Be About To Breakout To $250By Sam Quirke | June 19, 2025View Why Amazon Could Be About To Breakout To $250JAGX, YMTX, ARDS, and AEZS Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.49 -0.08 (-2.22%) As of 06/18/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Aridis Pharmaceuticals NASDAQ:ARDS$0.0001 0.00 (0.00%) As of 10:50 AM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Jaguar Animal Health NASDAQ:JAGX$2.80 +0.02 (+0.72%) Closing price 04:00 PM EasternExtended Trading$2.84 +0.04 (+1.25%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Yumanity Therapeutics NASDAQ:YMTXYumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
